Literature DB >> 24566274

Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors.

Seiko Toraya-Brown1, Mee Rie Sheen1, Peisheng Zhang1, Lei Chen1, Jason R Baird1, Eugene Demidenko2, Mary Jo Turk1,3, P Jack Hoopes4,5,3, Jose R Conejo-Garcia6, Steven Fiering1,7,3.   

Abstract

Combinatorial use of iron oxide nanoparticles (IONPs) and an alternating magnetic field (AMF) can induce local hyperthermia in tumors in a controlled and uniform manner. Heating B16 primary tumors at 43°C for 30 min activated dendritic cells (DCs) and subsequently CD8(+) T cells in the draining lymph node (dLN) and conferred resistance against rechallenge with B16 (but not unrelated Lewis Lung carcinoma) given 7 days post hyperthermia on both the primary tumor side and the contralateral side in a CD8(+) T cell-dependent manner. Mice with heated primary tumors also resisted rechallenge given 30 days post hyperthermia. Mice with larger heated primary tumors had greater resistance to secondary tumors. No rechallenge resistance occurred when tumors were heated at 45°C. Our results demonstrate the promising potential of local hyperthermia treatment applied to identified tumors in inducing anti-tumor immune responses that reduce the risk of recurrence and metastasis. FROM THE CLINICAL EDITOR: Local heating of tumors via iron oxide NPs and an alternating magnetic field led to activation of anti-cancer CD8 T cells, which resulted in resistance against re-challenge and greater resistance to secondary tumors. Similar local heating-based strategies may become an important weapon in enhancing tumor elimination via a naturally existing but attenuated immune response.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-tumor immune; Heat; Iron oxide; Local hyperthermia; Nanoparticle

Mesh:

Substances:

Year:  2014        PMID: 24566274      PMCID: PMC4119841          DOI: 10.1016/j.nano.2014.01.011

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  48 in total

1.  Multi-chaperone-peptide-rich mixture from colo-carcinoma cells elicits potent anticancer immunity.

Authors:  Changxin Huang; Jiangang Zhao; Zhaoyang Li; Da Li; Dajing Xia; Qingqing Wang; Hongchuan Jin
Journal:  Cancer Epidemiol       Date:  2010-05-06       Impact factor: 2.984

2.  Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine.

Authors:  Taoyong Chen; Jun Guo; Mingjin Yang; Xuhui Zhu; Xuetao Cao
Journal:  J Immunol       Date:  2011-01-17       Impact factor: 5.422

3.  Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway.

Authors:  K Suzue; X Zhou; H N Eisen; R A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Thermal dose determination in cancer therapy.

Authors:  S A Sapareto; W C Dewey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-06       Impact factor: 7.038

5.  Neutrophils secrete MIP-1 beta after adhesion to laminin contained in basement membrane of blood vessels.

Authors:  Kouji Chiba; Wenli Zhao; Jiang Chen; Jingxin Wang; Hong Yan Cui; Hiroshi Kawakami; Tetsuya Miseki; Hashino Satoshi; Junji Tanaka; Masahiro Asaka; Masanobu Kobayashi
Journal:  Br J Haematol       Date:  2004-12       Impact factor: 6.998

6.  Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake.

Authors:  S Todryk; A A Melcher; N Hardwick; E Linardakis; A Bateman; M P Colombo; A Stoppacciaro; R G Vile
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

Review 7.  Old and new facts about hyperthermia-induced modulations of the immune system.

Authors:  Benjamin Frey; Eva-Maria Weiss; Yvonne Rubner; Roland Wunderlich; Oliver J Ott; Rolf Sauer; Rainer Fietkau; Udo S Gaipl
Journal:  Int J Hyperthermia       Date:  2012-06-12       Impact factor: 3.914

8.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.

Authors:  C S Hsieh; S E Macatonia; C S Tripp; S F Wolf; A O'Garra; K M Murphy
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

9.  Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.

Authors:  Akira Ito; Kouji Tanaka; Kazuyoshi Kondo; Masashige Shinkai; Hiroyuki Honda; Kazuhiko Matsumoto; Toshiaki Saida; Takeshi Kobayashi
Journal:  Cancer Sci       Date:  2003-03       Impact factor: 6.716

10.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

Authors:  A Y Huang; P H Gulden; A S Woods; M C Thomas; C D Tong; W Wang; V H Engelhard; G Pasternack; R Cotter; D Hunt; D M Pardoll; E M Jaffee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  52 in total

1.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.

Authors:  Guoshuai Cao; Jian Wang; Xiaodong Zheng; Haiming Wei; Zhigang Tian; Rui Sun
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

Review 2.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 3.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

Review 4.  Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: Therapeutic benefits, toxicity, mechanistic insights, and translational considerations.

Authors:  Ankit Shah; Marina A Dobrovolskaia
Journal:  Nanomedicine       Date:  2018-02-02       Impact factor: 5.307

Review 5.  Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.

Authors:  Seyed Mohammadali Dadfar; Karolin Roemhild; Natascha I Drude; Saskia von Stillfried; Ruth Knüchel; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2019-01-11       Impact factor: 15.470

6.  Metallic Nanoparticles for Cancer Immunotherapy.

Authors:  Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal:  Mater Today (Kidlington)       Date:  2017-12-14       Impact factor: 31.041

7.  Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.

Authors:  Yang Liu; Pakawat Chongsathidkiet; Bridget M Crawford; Ren Odion; Cosette A Dechant; Hanna R Kemeny; Xiuyu Cui; Paolo F Maccarini; Christopher D Lascola; Peter E Fecci; Tuan Vo-Dinh
Journal:  Immunotherapy       Date:  2019-09-18       Impact factor: 4.196

Review 8.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

9.  Effect of intra-tumoral magnetic nanoparticle hyperthermia and viral nanoparticle immunogenicity on primary and metastatic cancer.

Authors:  P Jack Hoopes; Courtney M Mazur; Bjorn Osterberg; Ailin Song; David J Gladstone; Nicole F Steinmetz; Frank A Veliz; Alicea A Bursey; Robert J Wagner; Steven N Fiering
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2017-02-20

10.  Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy.

Authors:  Hayley J Paholak; Nicholas O Stevers; Hongwei Chen; Joseph P Burnett; Miao He; Hasan Korkaya; Sean P McDermott; Yadwinder Deol; Shawn G Clouthier; Tahra Luther; Qiao Li; Max S Wicha; Duxin Sun
Journal:  Biomaterials       Date:  2016-06-23       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.